Aslan Pharma Repurposes DHODH Inhibitor for Autoimmune, COVID-19 Indications
publication date: Oct 16, 2020
Singapore's Aslan Pharma announced plans to develop ASLAN003, its next-gen dihydroorotate dehydrogenase (DHODH) inhibitor in autoimmune conditions, such as multiple sclerosis (MS). It will also test the candidate as a treatment for COVID-19 and other viral infections. According to Aslan, ASLAN003 has shown 30 times the potency for inhibiting the DHODH enzyme in pre-clinical tests as first-gen molecules. In 2019, Aslan completed a Phase II trial of ASLAN003 in AML, but decided not to continue its development for the indication. More details....
Stock Symbols: (NSDQ: ASLN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.